Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-leading Dupixent.